Direct follow-up of the Amazon project, the Jackson project targets the development a range of products to allow wider implementation of telemedicine and patient data sharing through new technology and to access larger market segments through cardiac electro-therapy solutions.
The objective of this project is to augment the existing Tempus Pro device with new products and services, which will enable its wider adoption by healthcare providers. Additionally, the project will provide electrotherapy solutions to work with the Tempus Pro that will meet the needs of wider user groups and therefore open up new market segments.
The intended users of the system will be professional civlian medical personnel deployed in local-civic and remote scenarios via a variety of emergency response vehicles. Within this broad group are subgroups of other users whose needs can be differentiated from each other. These include:
RDT targets a range of pre-hospital care applications, mostly in Europe and Africa.
This project includes various hardware and software improvements to the existing Tempus Pro as well as the development of a stand-alone fully therapeutic defibrillator which can be used with the monitor. Also included is the development of a range of accessories, which are required by the civilian pre-hospital market.
The project also includes the development of an entirely new data portal supported by new and more robust communications interfaces. Used together, these devices will offer the pre-hospital care markets a significantly more configurable and scalable system. This system will meet the existing clinical (monitoring and therapy) requirements of pre-hospital care users but will allow them to:
This project will leverage the existing investment in space assets (satcom and GNSS data) that were established in the previous Amazon project and utilise them in much larger markets. Having established the use of these technologies in remote and real-time care in the Amazon project, the Jackson project will bring the use of the products into much greater use by introducing them into new, significantly larger markets.
While the current military and remote land markets are attractive markets, the civilian pre-hospital market is an even larger and more attractive market. Based on data from various sources, information from key OEM suppliers, and various European and US government reports the global market for civilian pre-hospital monitors is estimated to be approximately 160 000 units. This covers Europe, USA and sensible rest of world markets such as Australia, Canada and the Middle East. Assuming a replacement rate of once every five years, this scopes the annual market to be approximately 32 000 units per year.
Accessing these much larger markets would drive the use of the previous space technology investments.
RDT believes that its real-world experience of using satcom in remote telemedicine applications will add particular value and difference in these larger markets.
Since the Demo Qualification Review meeting successfully held at RDT premises in November 2017, the company has mainly been working on all elements of the deliverables including defibrillation and data access. Additionally, work has been performed on a range of accessories which are required for the successful launch of the product. The defibrillator (Temps LS) has a full CE mark has now been launched in to key adopter sites (September 2017). This includes leading UK HEMS sites and Dutch Ambulance Service. The modular system is collectively known as the “Tempus ALS”.
The Software platform (Corsium) is scheduled for release in October 2018. The System Deployment Acceptance meeting is scheduled for November 2018 in the UK.
Last but not least, RDT has been acquired in June 2018 by the Royal Philips medical systems manufacturer.